Announcement • Mar 31
Biomm S.A., Annual General Meeting, Apr 30, 2026 Biomm S.A., Annual General Meeting, Apr 30, 2026. Location: 705 regent avenue, plots 15-21, part, block 28, alphaville lagoados ingleses, nova lima, state of minas gerais, Brazil Reported Earnings • Mar 27
Full year 2025 earnings released: R$0.05 loss per share (vs R$0.63 loss in FY 2024) Full year 2025 results: R$0.05 loss per share (improved from R$0.63 loss in FY 2024). Revenue: R$269.3m (up 88% from FY 2024). Net loss: R$6.69m (loss narrowed 91% from FY 2024). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth. New Risk • Nov 21
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Brazilian stocks, typically moving 8.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-R$140m free cash flow). Share price has been highly volatile over the past 3 months (8.9% average weekly change). Reported Earnings • Nov 19
Third quarter 2025 earnings released: R$0.08 loss per share (vs R$0.13 loss in 3Q 2024) Third quarter 2025 results: R$0.08 loss per share (improved from R$0.13 loss in 3Q 2024). Revenue: R$35.8m (up 11% from 3Q 2024). Net loss: R$10.6m (loss narrowed 35% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 17
Second quarter 2025 earnings released: R$0.11 loss per share (vs R$0.14 loss in 2Q 2024) Second quarter 2025 results: R$0.11 loss per share (improved from R$0.14 loss in 2Q 2024). Revenue: R$27.2m (down 15% from 2Q 2024). Net loss: R$13.7m (loss narrowed 25% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Reported Earnings • May 16
First quarter 2025 earnings released: R$0.10 loss per share (vs R$0.15 loss in 1Q 2024) First quarter 2025 results: R$0.10 loss per share (improved from R$0.15 loss in 1Q 2024). Revenue: R$39.6m (up 2.7% from 1Q 2024). Net loss: R$11.7m (loss narrowed 31% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 31
Full year 2024 earnings released: R$0.63 loss per share (vs R$0.97 loss in FY 2023) Full year 2024 results: R$0.63 loss per share (improved from R$0.97 loss in FY 2023). Revenue: R$142.9m (up 21% from FY 2023). Net loss: R$77.2m (loss narrowed 4.8% from FY 2023). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Announcement • Mar 31
Biomm S.A., Annual General Meeting, Apr 29, 2025 Biomm S.A., Annual General Meeting, Apr 29, 2025. Location: 705 regent avenue, plots 15-21, part, block 28, alphaville lagoados ingleses, nova lima, state of minas gerais., nova lima Brazil New Risk • Feb 27
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Brazilian stocks, typically moving 9.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.9% average weekly change). Earnings have declined by 7.6% per year over the past 5 years. Shareholders have been substantially diluted in the past year (56% increase in shares outstanding). Reported Earnings • Nov 17
Third quarter 2024 earnings released: R$0.13 loss per share (vs R$0.27 loss in 3Q 2023) Third quarter 2024 results: R$0.13 loss per share (improved from R$0.27 loss in 3Q 2023). Revenue: R$32.3m (down 2.6% from 3Q 2023). Net loss: R$16.3m (loss narrowed 26% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 16
Second quarter 2024 earnings released: R$0.14 loss per share (vs R$0.25 loss in 2Q 2023) Second quarter 2024 results: R$0.14 loss per share (improved from R$0.25 loss in 2Q 2023). Revenue: R$32.1m (up 4.3% from 2Q 2023). Net loss: R$18.3m (loss narrowed 9.6% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. New Risk • May 30
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 56% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 12% per year over the past 5 years. Shareholders have been substantially diluted in the past year (56% increase in shares outstanding). Reported Earnings • May 18
First quarter 2024 earnings released: R$0.15 loss per share (vs R$0.22 loss in 1Q 2023) First quarter 2024 results: R$0.15 loss per share (improved from R$0.22 loss in 1Q 2023). Revenue: R$38.6m (up 13% from 1Q 2023). Net loss: R$17.1m (loss narrowed 4.7% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has remained flat. Reported Earnings • Mar 28
Full year 2023 earnings released Full year 2023 results: Revenue: R$118.2m (up 13% from FY 2022). Net loss: R$81.1m (loss narrowed 12% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 14% per year, which means it is performing significantly worse than earnings. New Risk • Feb 10
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 56% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-R$77m free cash flow). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (56% increase in shares outstanding). Reported Earnings • Nov 19
Third quarter 2023 earnings released: R$0.27 loss per share (vs R$0.34 loss in 3Q 2022) Third quarter 2023 results: R$0.27 loss per share (improved from R$0.34 loss in 3Q 2022). Revenue: R$33.1m (up 7.8% from 3Q 2022). Net loss: R$21.9m (loss narrowed 13% from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 29% per year, which means it is performing significantly worse than earnings. New Risk • Oct 25
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Brazilian stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-R$86m free cash flow). Share price has been highly volatile over the past 3 months (9.1% average weekly change). Earnings have declined by 17% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (11% increase in shares outstanding). Market cap is less than US$100m (R$405.6m market cap, or US$81.2m). Announcement • Oct 07
Biomm S.A. to Report Q3, 2023 Results on Nov 13, 2023 Biomm S.A. announced that they will report Q3, 2023 results at 6:00 PM, E. South America Standard Time on Nov 13, 2023 Reported Earnings • Aug 12
Second quarter 2023 earnings released: R$0.25 loss per share (vs R$0.33 loss in 2Q 2022) Second quarter 2023 results: R$0.25 loss per share (improved from R$0.33 loss in 2Q 2022). Revenue: R$30.8m (up 37% from 2Q 2022). Net loss: R$20.2m (loss narrowed 16% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 29% per year, which means it is performing significantly worse than earnings. New Risk • Aug 09
New major risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Brazilian stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-R$85m free cash flow). Earnings have declined by 19% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Shareholders have been diluted in the past year (11% increase in shares outstanding). Reported Earnings • Mar 24
Full year 2022 earnings released: R$1.26 loss per share (vs R$1.19 loss in FY 2021) Full year 2022 results: R$1.26 loss per share (further deteriorated from R$1.19 loss in FY 2021). Revenue: R$105.0m (down 2.0% from FY 2021). Net loss: R$92.6m (loss widened 15% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings. Board Change • Nov 16
No independent directors There are 7 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 7 new directors. 2 experienced directors. 3 highly experienced directors. No independent directors (7 non-independent directors). Director Ítalo Gaetani is the most experienced director on the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. Reported Earnings • Aug 14
Second quarter 2022 earnings released: R$0.33 loss per share (vs R$0.20 loss in 2Q 2021) Second quarter 2022 results: R$0.33 loss per share (down from R$0.20 loss in 2Q 2021). Revenue: R$22.5m (down 35% from 2Q 2021). Net loss: R$24.2m (loss widened 79% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Announcement • May 20
Biomm S.A. to Report Q2, 2022 Results on Aug 11, 2022 Biomm S.A. announced that they will report Q2, 2022 results on Aug 11, 2022 Board Change • Apr 27
No independent directors There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: No independent directors. 8 non-independent directors. Alternate Director Newton Maia Alves was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Announcement • Mar 31
Biomm S.A. to Report Q1, 2022 Results on May 13, 2022 Biomm S.A. announced that they will report Q1, 2022 results at 10:00 PM, Coordinated Universal Time on May 13, 2022 Reported Earnings • Mar 30
Full year 2021 earnings released Full year 2021 results: Revenue: R$107.1m (up 83% from FY 2020). Net loss: R$80.3m (loss widened 13% from FY 2020). Post-clinical trial products Approved (during full year): 1 Launched (during full year): 1 Announcement • May 28
Biomm S.A. Announces Plans to Submit Authorization to Conduct Phase 3 Clinical Studies of Leronlimab with ANVISA in Brazil in the Next Few Days Biomm S.A. announced that it is planning to submit an authorization request to the Brazilian National Health Surveillance Agency (“ANVISA”) in the next few days to conduct two Phase 3 clinical trials of leronlimab in Brazil for COVID-19. The two Phase 3 trials consist of trials for each severe and critically ill COVID-19 patients. Once approved by ANVISA, the Phase 3 trials will be conducted by Albert Einstein Israelite Hospital, an Academic Research Organization in Brazil. The COVID-19 trials in Brazil are intended to provide ANVISA with the requisite data to consider advancing the availability of leronlimab to thousands of Brazilians infected with COVID-19. These two Phase 3 trials will be conducted in up to 45 clinical sites. The critically ill protocol is for 306 patients while the severe protocol is for 594 patients, and interim analysis for both populations will be conducted when enrollment reaches about 40% of the total number for each trial. Reported Earnings • Mar 30
Full year 2020 earnings released The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2020 results: Revenue: R$58.7m (up R$49.7m from FY 2019). Net loss: R$70.8m (loss widened 27% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 31% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Feb 11
New 90-day low: R$14.95 The company is down 9.0% from its price of R$16.49 on 12 November 2020. The Brazilian market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 19% over the same period. Is New 90 Day High Low • Jan 27
New 90-day low: R$15.55 The company is down 3.0% from its price of R$16.00 on 28 October 2020. The Brazilian market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 21% over the same period. Is New 90 Day High Low • Jan 07
New 90-day low: R$15.86 The company is down 3.0% from its price of R$16.28 on 09 October 2020. The Brazilian market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 8.0% over the same period. Announcement • Dec 19
Bio-Thera Solutions Announces Licensing Agreement with Biomm S.A. to Distribute and Market BAT1706 in Brazil Bio-Thera Solutions announced the company has reached a licensing agreement with Biomm S.A. for BAT1706, its bevacizumab biosimilar, under which Biomm will have exclusive rights to distribute and market the drug in Brazil. BAT1706 is a proposed bevacizumab biosimilar for the treatment of patients with metastatic colorectal cancer, metastatic or locally recurrent breast cancer, locally advanced, metastatic or recurrent non-small cell lung cancer, metastatic renal cell carcinoma, persistent, recurrent, or metastatic cervical cancer, and epithelial ovarian, fallopian tube, or primary peritoneal cancer. Bio-Thera’s BAT1706 has successfully completed a global Phase III comparative clinical study which was a multicenter, randomized, double blind, study evaluating the efficacy, safety, pharmacokinetics and immunogenicity of BAT1706 versus EU-bevacizumab plus chemotherapy in patients with advanced non squamous non-small cell lung cancer. Bio-Thera has filed the commercial license application for BAT1706 with the China National Medical Products Administration (NMPA) and also more recently with the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA). Biomm will be responsible for filing the dossier in Brazil. This partnership will leverage Biomm’s strong local presence, sales and marketing capabilities in Brazil. Bio-Thera will be responsible for full development, and commercial supply of BAT1706 out of its manufacturing facilities in Guangzhou, China. Is New 90 Day High Low • Oct 30
New 90-day high: R$17.10 The company is up 7.0% from its price of R$15.92 on 31 July 2020. The Brazilian market is down 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 4.0% over the same period. Announcement • Oct 06
Biomm S.A. to Report Q3, 2020 Results on Nov 06, 2020 Biomm S.A. announced that they will report Q3, 2020 results on Nov 06, 2020 
